Irish pharma firm Amryt nears approval for butterfly skin treatment
EMA has 67 days to decide whether to back recommendation of its expert committee
Amryt prepares share buyback amid €110m debt refinancing
Dublin-based biopharma group says most of the funds to be used to repay existing loan
Irish pharma group Amryt reports 15% revenue growth for third quarter
Rare disease specialist says performance was ‘strong’ in ‘extremely busy’ period
Record sales for Irish rare disease specialist Amryt
Company upgrades forecasts as it completes Chiasma takeover
Dublin-based Amryt buys US firm Chiasma in deal worth $330m
Drug group expands its portfolio of medicines while reporting first-quarter numbers
Amryt acquires company with plans to grow portfolio
Group plots dual Nasdaq listing to create enlarged rare disease company
Amryt gets 2019 off to strong start following 13% revenue rise in 2018
Lojuxta revenues driven by UK, France reimbursement approval
Amryt reports strong 2017 as revenues rise to almost €13m
Biopharma firm signs new deal for gene therapy that could treat genetic condition EB
Amryt signs new distribution deal for Lojuxta
Latest deal is fourth in three months for Ierish biopharmaceutical company
Amryt shares jump on deal to sell cholesterol disorder drug
Licence agreement said to cover €8m of annualised sales in Europe and Middle East
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices